Justices Asked To Ban FCA Suits Relying On Patent Reviews
By Andrew Karpan · April 10, 2024, 6:06 PM EDT
Valeant Pharmaceuticals is going to the U.S. Supreme Court to argue that information cited in Patent Trial and Appeal Board reviews cannot later be used by whistleblowers in False Claims Act...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login